It is well known that only 1 of the questions on the BASDAI is specific to axial symptoms, whereas the ASDAS excludes the evaluation of enthesitis, gives less preference to peripheral activity.
Rates of tophus resolution increased in patients in both groups between week 24 and week 52, suggesting that the therapeutic benefits of pegloticase and MTX may extend beyond 6 months.
Pregnant patients who were enrolled in the registry between March 2020 and February 2022 were eligible for inclusion.
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
Researchers conducted a 6-year longitudinal cohort study that analyzed the impact of glucocorticoid intake at varying doses
Researchers sought to explore the effectiveness of switching between the infliximab biosimilars CT-P13 and GP1111.
All participants’ responses were linked to their most recent semiannual questionnaire with regard to demographics, primary diagnosis, and patient-reported outcomes.
Patients with vasculitis aged older than 40 years who had been admitted to teaching hospitals were included in the study.
Participants were randomly assigned 1:1:1 to receive secukinumab 150mg, secukinumab 300mg, or adalimumab biosimilar 40mg, for 104 weeks.
The analysis included 140 patients from the SELECT-BEYOND cohort and 258 patients from the SELECT-CHOICE cohort.
Want to read more?
Please login or register first to view this content.